Midatech will host a conference call and live Q&A session today (Monday 30 September 2019) at 1400 BST / 0900 EDT for analysts and investors to discuss the 2019 Interim Results. Dr Craig Cook, Chief Executive Officer, an

Midatech will host a conference call

and live Q&A session today (Monday 30 September 2019) at 1400 BST / 0900 EDT for analysts and investors to discuss the 2019

Interim Results. Dr Craig Cook, Chief Executive Officer, and Stephen Stamp, Chief Financial Officer, will lead the presentation.

The conference call dial-in details

are: UK: +44 (0)20 3003 2701, US: +1 646 843 4609, Conference PIN: 9745561.

The presentation will be available on

Midatech's website shortly before the call.

("Midatech", "Company"

Interim results for the six months ended

Midatech (AIM: MTPH.L; Nasdaq: MTP), the

R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces its results

for the six months ended 30 June 2019.

OPERATIONAL HIGHLIGHTS (including

FINANCIAL HIGHLIGHTS

Commenting on the Full Year 2018 Results,

Midatech's Chief Executive Officer, Dr Craig Cook, said: "The first half of this year saw us achieve some important

milestones. Alongside a successful fundraise we secured our largest ever licensing partnership for our technology with CMS. We

have moved our in-house programmes forward and now have a clear, deliverable development plan for our lead product MTD201, together

with the exciting potential of our MTX110 programme, with further clinical data expected from both programmes in the near term."

For more information, please contact:

contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs

in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide

compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment

for life threatening diseases.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

By improving biodelivery and biodistribution

of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,

accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies

allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility

is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom

and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech

to successfully test, manufacture, produce or commercialize products for conditions using its technology platforms, and the ability

for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with

pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available

competitive, financial and economic data together with management's views and assumptions regarding future events and business

performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there

are some known and unknown factors that could cause actual results to differ materially from any future results, performance or

achievements expressed or implied by such forward-looking statements.

be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance

with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs")

and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important

factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.

These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking

statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may

be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake

any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise

CHAIRMAN AND CHIEF EXECUTIVE'S REVIEW

The first half of 2019 has seen Midatech

continue to make important progress on all fronts. Our key R&D programmes, MTD201 (Q-Octreotide) for the treatment of acromegaly

and neuroendocrine tumours, and MTX110 for the treatment of childhood brain cancer, have both progressed in their development.

Furthermore, in February, we signed our first major licence deal, with Chinese specialty pharmaceutical group, China Medical System

("CMS"), and concluded a round of fundraising, securing 13.4 million before transaction costs, extending the

cash runway into 2020. We also restructured the Board of Directors, reducing the size of the Board overall whilst welcoming two

new Non-Executive Directors, both bringing very significant pharmaceutical industry expertise.

Fundraise, CMS investment and licence

The licence deal with CMS accompanied an

8 million investment by CMS and A&B, for a 51% stake in Midatech, and is an important validation of our pipeline products,

platform technologies, intellectual property portfolio and commercial potential. To be able to secure a such credible regional

partner is a hugely significant development for Midatech and brings not only significant commercialisation and distribution capabilities

in Asia but also opportunity for development of earlier stage assets outside of our core products. Subject to certain milestones

being achieved, pursuant to the terms of the licence agreement entered into between Midatech and CMS ("Licence"), Midatech,

will receive regulatory and sales-based payments, as well as royalties.

Through the Licence, CMS has acquired rights

to develop and commercialise (at its cost) our pipeline product candidates in Greater China and certain countries in South East

Asia (not including Japan and South Korea). CMS currently promotes a wide range of licenced pharmaceutical products through its

network of around 3,600 staff in China.

As previously announced, the Licence also

allows CMS to pursue additional product opportunities using Midatech's technologies beyond those currently in development,

with the opportunity for CMS to fund Midatech to undertake the initial development on CMS' behalf. If such products were

to obtain regulatory approval, CMS would own the rights in the territories covered by the agreement and Midatech would retain the

rights in the rest of the world, including the US and Europe. Initial feasibility work is already underway on one programme with

others having been identified by CMS for further evaluation.

With our unique platform technologies,

Midatech seeks to make medicines better, improving the bio-delivery and bio-distribution of existing, approved drug compounds by

taking them to where they are needed in the body, enabling them to exert their actions in an effective, safe and precise manner.

This de-risked approach is bearing fruit with both MTD201 (Q-Octreotide) and MTX110 successfully entering the clinic in May 2018

and both are now making good progress on their routes to market.

The two lead programmes form part of a

compelling pipeline of oncology and immunotherapy assets progressing towards and through clinical development. Following significant

restructuring last year, Midatech now has a clear R&D focussed strategy to deliver transformative therapies that might otherwise

not be possible, or be very difficult, for patients with devastating cancers and other rare diseases. In addition, the programmes

currently at the preclinical stage offer the potential to add to our exciting R&D pipeline in the mid-term.

MTD201 for acromegaly and neuroendocrine

Midatech's lead development product,

MTD201 (Q-Octreotide), is a treatment for acromegaly and neuroendocrine tumours ("NET"), and is based on the Group's

unique, proprietary polymer microsphere technology, Q-Sphera for sustained release delivery. MTD201 will enter a $2.5 billion

market, currently dominated by a Novartis product, Sandostatin LAR ("SLAR").

Following the successful, Phase I human

study conducted in 2018 ("Study 101"), which compared the performance of MTD201 against SLAR, we have now finalised

the development plan for the product. The 2018 study indicated that MTD201 has a number of product characteristics, uniquely conferred

by the Q-Sphera technology, that support the positioning of MTD201 as a new differentiated product for the treatment of acromegaly

and NET. Following consultations with key opinion leaders, regulators, and potential partners, we believe that leveraging these

benefits and developing MTD201 as a differentiated product provides the most valuable, de-risked development programme for the